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ABSTRACT
Glomerular targets of autoimmunity in human membranous nephropathy are poorly understood. Here,
we used a combined proteomic approach to identify specific antibodies against podocyte proteins in
both serum and glomeruli of patients with membranous nephropathy (MN). We detected specific
anti–aldose reductase (AR) and anti–manganese superoxide dismutase (SOD2) IgG4 in sera of patients
with MN. We also eluted high titers of anti-AR and anti-SOD2 IgG4 from microdissected glomeruli of
three biopsies of MN kidneys but not from biopsies of other glomerulonephritides characterized by IgG
deposition (five lupus nephritis and two membranoproliferative glomerulonephritis). We identified both
antigens in MN biopsies but not in other renal pathologies or normal kidney. Confocal and immuno-
electron microscopy (IEM) showed co-localization of anti-AR and anti-SOD2 with IgG4 and C5b-9 in
electron-dense podocyte immune deposits. Preliminary in vitro experiments showed an increase of
SOD2 expression on podocyte plasma membrane after treatment with hydrogen peroxide. In conclu-
sion, our data support AR and SOD2 as renal antigens of human MN and suggest that oxidative stress
may drive glomerular SOD2 expression.
J Am Soc Nephrol 21: 507–519, 2010. doi: 10.1681/ASN.2008121259
Primarymembranous nephropathy (MN) is a com-
mon glomerular disease in humans with no univer-
sally effective clinical therapy. Treatments are en-
tirely empirical, and the disease evolves toward
renal failure in a significant number of patients.1,2
The presence of glomerular subepithelial immune
deposits is the distinctive pathologic feature ofMN,
thus supporting the concept of an immunologic or-
igin. It is also known that inflammatory com-
pounds such as complement, oxygen radicals,3,4 or
intracellular protein kinase C5 may participate,
having a key role in disease progression.
In the past few decades, studies of experimental
models, with a particular emphasis on the Hey-
mann nephritis (HN)model,6–8 have led to the iden-
tification of antigens of the autoantibody response in
rats (megalin),7 mice (aminopeptidase A),9 and rab-
bits (neutral endopeptidase [NEP]),10–12 but lim-
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ited data are available for humans. Moreover, megalin, which
is the target antigen in HN, is absent in human glomeruli, and
the LDL receptor, its human homolog, is only partially co-
localized with MN IgG deposits.5,13–15 Seminal studies by De-
biec et al.11,12 support the formation of immune deposits
against NEP, in particular, cases withmetallomembrane endo-
peptidase mutations that lead to NEP deficiency and alloim-
munization during pregnancy. More recently, Beck et al.16 re-
ported the presence of specific IgG4 against the M-type
phospholipase A2 receptor (PLA2R) in glomerular eluates and
in plasma of a significant percentage of patients withMN, sug-
gesting PLA2R is a major antigen in this disease.
Unequivocal identification of coexisting antigens in the
podocyte membrane and in subepithelial deposits is essential
for any progression in the understanding of themechanisms of
MN in humans. The aim of this study was to identify podocyte
proteins recognized by circulating autoantibodies in patients
withMN, to define their expression in glomeruli, and to quan-
tify the levels of specific antibodies in sera and in renal biopsies.
Results provide first evidence for de novo expression of specific
autoantibodies against aldose reductase (AR) and superoxide
dismutase 2 (SOD2) in sera and glomeruli of patients with
MN.
RESULTS
Circulating Antibodies against Podocyte Proteins
in MN
Sera from patients with MN (Table 1) were screened for pres-
ence of autoantibodies against transblotted human podocyte
membrane extracts separated by two-dimensional (2D) elec-
trophoresis. Podocyte proteins recognized by human IgGwere
characterized by matrix-assisted laser desorption/ionization
time of flight (MALDI-TOF; Figure 1A, Table 2). As shown in
Figure 1, B and C, few proteins had been repetitively recog-
nized by MN sera: SOD2 (spots 1, 2, 3, and 4, positive in 10
cases), AR (spots 13, 14, and 15, positive in three cases),-eno-
lase (spots 16 and 17, positive in four cases), secernin-1 (spots
21 and 22, positive in five cases), ubiquitin hydrolase (spots 6
and 7, positive in seven cases), and ser/thr protein phosphatase
2A (spots 23 and 24, positive in seven cases). Identification of
AR and SOD2was further confirmed byWestern blot (Supple-
mental Figure 1).
AR and SOD2 were localized at the cell surface in nonper-
meabilized podocytes (Figure 1, D and G, and Supplemental
Figure 2, A through C and E through G), where they co-local-
ized with serum IgG obtained from patients with MN (Figure
1, F through I). Permeabilized cells showed, instead, a diffuse
AR cytoplasmic staining (Supplemental Figure 2D), whereas
SOD2 was limited to cell mitochondria (Supplemental Figure
2, H throughM). Podocyte biotin labeling confirmed presence
of SOD2 and AR on plasma membrane (Supplemental Figure
1A).
Taken together, results of this set of experiments showed T
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that MN sera contain IgG recognizing several podocyte anti-
gens. AR and SOD2 analysis was extended to determine their
serum titer, renal expression, and co-localization within glo-
merular structures with IgG4.
Serum Titer of Anti-AR and Anti-SOD2 Antibodies
After the observation in the previous section, we devised a new
assay to assess the titer of circulating anti-AR and anti-SOD2
antibodies in an amplified set of 24 MN sera. The assay was
based on dot-blot analysis with peroxidase detection of
IgG1 to 4 linked tomembrane-fixed antigens. The assay (see the
Concise Methods section and supplemental material), using
recombinant AR (r-AR) or SOD2 (r-SOD2) spotted as anti-
gens, proved to be sensitive to the nanogram level. Moreover,
as expected, recombinant proteins were constituted by a single
band at 36 and 48 kD, respectively, and were recognized as a
single band by sera of patients with MN (Supplemental Figure
3). Results shown in Figure 2 documented an increase in serum
Figure 1. Sera of MN patients show presence of antibodies against podocyte proteins. (A through C) 2D electrophoresis analysis of
podocyte membrane extracts and Western blot analysis of MN serum for anti-podocyte antibodies. (A) Representative 2D map of
podocyte membrane extracts stained by colloidal Coomassie. Numbers correspond to identified proteins as displayed in Table 2; spots
1, 2, 3, and 4 correspond to SOD2, and spots 13, 14, and 15 correspond to AR. (B and C) Western blot analysis of MN serum for
anti-podocyte antibodies. Sera of patients with MN were largely positive for SOD2 (B and C); only a few were positive for AR (C).
Representative normal sera (n  10) run in parallel to MN samples were negative and have been reported as control. (D through I)
Expression of AR and SOD2 on cultured podocytes. Nonpermeabilized human podocyte cell line stained for AR (D) or SOD2 (G) and
MN sera (10% in medium) incubated with cells (E and H). (F and I) Merged images. Arrows in merged images indicate the coexpression
of AR or SOD2 with MN IgG. Magnification, 630.
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levels of both anti-AR and anti-SOD2 IgG4 in MN sera (n 
24) compared with idiopathic FSGS (n  8) and normal sera
(n  24; nonparametric Mann-Whitney U test P  0.001 for
MN versus FSGS and P 0.01 for MN versus normal for both
antibodies). The difference was especially evident for SOD2
IgG4. It is relevant to note that no patient in FSGS group had
detectable levels of circulating IgG4 autoantibodies, whereas
50% of patients with MN showed presence of specific IgG4.
Dot blots with total IgG were less positive, whereas other IgG
subclasses were negative (data not shown).
De Novo Glomerular Expression of AR and SOD2
We investigated renal expression of AR and SOD2 by immu-
nofluorescence (IF) on renal tissues from patients with MN,
minimal-change disease (MCD), or IgA nephropathy or nor-
mal patients using commercially available polyclonal anti-
SOD2 antibody and highly purified polyclonal anti-AR (pro-
vided by P. Kador; see supplemental material). One patient
who had secondary MN with suspected neoplasia was also
added to the study.
AR and SOD2 were markedly and specifically expressed
in glomeruli of all patients with primary MN (Figure 3, E
and F), whereas both AR and SOD2 were absent in patients
with MCD (Figure 3, H and I) or in normal renal tissues
(Figure 3, B and C). Blocking experiments with increasing
amount of r-AR or r-SOD2 abolished AR and SOD2 stain-
ing, demonstrating specificity of antibodies used (Supple-
mental Figure 4). AR was minimally and focally expressed in
patients with IgA nephropathy (data not shown) and in the
patient with secondaryMN (Figure 3M), whereas SOD2 was
totally negative (Figure 3N). Patients with type 2 diabetes
(n 2) showed a mild mesangial expression of AR (data not
shown) and no expression of SOD2.
As expected, AR was not detectable at the cortical tubular
level (data not shown) in the normal kidney and in patients
with other renal pathologies, whereas a tubular staining for
SOD2 was observed in these groups. Quantitative analysis of
AR and SOD2 expression was assessed through IF morpho-
metric evaluation (Figure 3, O and P).
Renal Localization of AR and SOD2 by IEM
IEM for AR and SOD2 was performed in patients (n  3)
affected by stage 2 MN. These patients were selected among
those with positivity for AR and SOD2 circulating antibodies.
AR (Figure 4) and SOD2 (Figure 5) were expressed in the
podocyte cytoplasm and along the podocyte plasma mem-
brane (see Figure 4, C andD, for AR and Figure 5, C through E,
for SOD2), whereas they were absent in nuclei (Figure 4E).
Notably, several gold particles were clearly found in glomeru-
lar basement membrane (GBM) in the context of electron-
dense subepithelial immune deposits (Figure 4, A and B, for
AR and Figure 5, A and B, for SOD2). Controls were obtained
by omitting specific primary antibodies or using them after
preincubation with nonimmune goat serum (Figures 4F and
5F, Supplement Figure 5). Overall, these results confirmed the
expression of both AR and SOD2 in the cytoplasm and on
Table 2. MALDI-TOF characterization of proteins shown in Figure 1A
Spot Protein Name
Accession
No.
Score Coverage
1 Superoxide dismutase, mitochondrial p04179 60.33 76.13
2 Superoxide dismutase, mitochondrial p04179 60.33 76.13
3 Superoxide dismutase, mitochondrial p04179 238.33 75.20
4 Superoxide dismutase, mitochondrial p04179 238.23 75.20
5 Ubiquitin carboxyl-terminal hydrolase isoenzyme L1 p09936 120.33 47.50
6 Ubiquitin carboxyl-terminal hydrolase isoenzyme L1 p09936 120.33 47.50
7 Ubiquitin carboxyl-terminal hydrolase isoenzyme L1 p09936 120.33 47.50
8 Triosophosphato isomerasi p60174 120.29 43.80
9 Triosophosphato isomerasi p60174 120.29 43.80
10 Triosophosphato isomerasi p60174 120.29 43.80
11 Delta(3,5)-delta (2,4)-dienoyl-CoA isomerase, mitochondrial q13011 78.29 30.20
12 S-formylglutathione hydrolase p10768 130.32 66.70
13 Aldose reductase p15121 186.37 52.20
14 Aldose reductase p15121 186.37 52.20
15 Aldose reductase p15121 186.37 25.20
16 -Enolase p06733 178.40 38.70
17 -Enolase p06733 178.40 38.70
18 Vimentin p08670 280.34 38.50
19 Vimentin p08670 280.34 38.50
20 Elongation factor 2 p13639 390.34 45.20
21 Secernin-1 q12765 200.32 56.80
22 Secernin-1 q12765 180.31 51.90
23 Highly similar ser/thr protein phosphatase 2A q8nb89 140.31 30.30
24 Highly similar ser/thr protein phosphatase 2A q8nb89 140.31 30.30
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plasma membrane of podocytes of patients with MN. IEM
clearly indicated presence of both AR and SOD2within subep-
ithelial immune deposits.
Glomerular AR and SOD2 Co-localize with IgG4 and
C5b-9
Confocal microscopy further confirmed IEM results and spe-
cifically indicated co-localization of ARwith both IgG4 (Figure
6, A through C and p1) and C5b-9 (Figure 7, A through C and
p1) and SOD2 with the same IgG4 and C5b-9 (Figures 6, D
through F and p2, and 7, D through F and p2) along GBM
deposits.
Renal IgG4 from MN Recognizes AR and SOD2
Further experiments were done microdissecting glomeruli of
three patients who had MN and were positive for circulating
Figure 3. AR and SOD2 are expressed in renal biopsies of MN
patients. (A through N) Representative images of renal biopsy
specimens from normal patients (A through C), and patients with
MN (D through F), MCD (G through I), and MN secondary to
neoplasia (L through N) stained for synaptopodin (A, D, G, and L),
AR (B, E, H, and M), or SOD2 (C, F, I, and N). AR and SOD2
staining is absent in tissues from normal individuals normal and
from patients with MCD and only very weakly expressed in tissues
from patients with MN secondary to neoplasia, whereas a marked
glomerular staining for both proteins is evident in patients with
MN. Synaptopodin is included to highlight glomerular structures.
Bar  200 . (O and P) Morphometric results of glomerular
expression of AR and SOD2 in patients with MN. Bar graph shows
glomerular expression of AR (f) and SOD2 (), as measured by
morphometric analysis on tissues from studied cases. Results are
expressed as percentage of the positive area for each considered
antibody on total glomerular area. The protein expression for
both was increased in patients with MN, with high statistical
significance (P  0.001) when compared with control patients
with a higher expression of AR in all considered glomeruli. Mag-
nification, 400.
Figure 2. Circulating anti-AR and anti-SOD2 antibodies are
present in the sera of MN patients and completely absent in
FSGS. (A and C) MN sera (n  24, first two rows) screened for the
presence of autoantibodies were positive for both anti-AR (A) and
anti-SOD2 (C) IgG4. Intensity was mild or absent in normal sera
(n  24, bottom rows) and completely absent in FSGS (NS). St.,
calibration curve. (B and D) Corresponding dot graphs plotting
OD for both anti-AR (B) and anti-SOD2 (D) IgG4. Nonparametric
statistical tests (Mann-Whitney U test) showed a statistical differ-
ence between MN and normal sera (N) in all cases (P  0.01 for
anti-AR and P  0.001 for anti-SOD IgG4; the difference between
MN and FSGS was P  0.001 in all cases).
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anti-AR and SOD antibodies (Figures 8 through 10). Igs eluted
from laser-captured MN glomeruli and blotted in comparable
amounts (Figure 10) against whole podocyte extracts con-
firmed reactivity of eluted IgG4with a panel of proteins includ-
ing AR and SOD2. Podocyte proteins were separated in both
reducing and nonreducing conditions. In the former case (Fig-
ure 8, a through e),microeluted IgG4 recognized eight bands in
a range ofmolecular weight between 10 and 120 kD. Themajor
two were characterized as vimentin and its fragments; besides
AR and SOD that were recognized by mass spectrometry and
Western blot (Figure 8, d and e), there were four bands with
molecular weight of 90, 55, 40, and 9 kD, respectively. Overall
and with the exception of vimentin, which is a cytoskeletal
protein, AR and SOD2 concentrationwas comparable with the
other components, supporting that they are major antigens in
MN. As expected, more proteins were detected by electro-
phoresis in nonreducing conditions, and Western blot con-
firmed reactivity of IgG4 withmost of the components already
found in reducing gels (Figure 8, f through h). In fact, three
proteins with an apparent molecular weight of 200, 170, and
155 kD, respectively, were recognized by IgG4, the second of
which is compatible with PLA2R.
The same dot blot used for titration of circulating antibod-
ies was also used for detection of specific antibodies against
r-AR and r-SOD2 in glomerular eluates. Biopsies of three dif-
ferent patients withMN and other patients with glomerulone-
phritis characterized by glomerular IgG deposition (five with
lupus nephritis class III or IV glomerulonephritis and twowith
membranoproliferative lesions) were evaluated using anti-to-
tal IgG and anti-IgG subclasses 1 through 4. Results shown in
Figure 9 and 10 (for IgG4) and in Supplemental Figure 6 (for
other IgGs) clearly demonstrated the presence of anti-AR and
anti-SOD2 IgG4 in glomeruli of patients with MN and their
absence in other renal pathologies. Reactivity of IgG4was abol-
ished by pretreating sera with increasing amounts of r-AR or
r-SOD2 (5 and 15 ng), thus confirming antibody specificity
(Figure 9C).
Figure 4. AR is present in GBM and in subepithelial immune
deposits. (A and B) AR is present in GBM as shown by several
scattered gold particles in the context of electron-dense subep-
ithelial immune deposits (arrows). (C through E) AR was also
observed in the cytoplasm and the plasma membrane of podo-
cyte bodies (Po). (E) AR is not expressed at the nuclear (N) level;
instead, AR is present in the cytoplasm as indicated by arrows. (F)
Blank sample lacking primary antibody was totally negative (see
also Supplemental Figure 5, A, C, and E). EN, endothelium.
Magnifications: 8900 in A; 56,000 in B, D, and E; 36,000 in
C; 44,000 in F.
Figure 5. SOD2 is present in GBM and on podocyte plasma
membrane. (A and B) SOD2 was detected in electron-dense
immune deposits within the GBM (arrows) as shown by several
scattered gold particles. (C and D) SOD2 was also observed in the
cytoplasm and on plasma membrane of podocyte bodies (Po). (F)
Blank sample omitting specific primary antibody was totally neg-
ative (see also Supplemental Figure 5, B, D, and F), EN, endo-
thelium; n, podocyte nucleus. Magnifications: 8900 in A;
44,000 in B and C; 71,000 in D; 51,000 in E; 36,000 F.
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Podocyte SOD2 Expression Is a Cellular Response to
Oxidation
As evidenced in the previous section, immortalized human
podocyte cell line spontaneously expresses AR (Figure 1, D
through F) and SOD2 (Figure 1, G through I) on plasmamem-
brane (see also Supplemental Figure 1, A through C and E
through G). This finding was also confirmed by biotinilization
experiments (Supplemental Figure 2). Increased SOD2 expres-
sion on plasma membrane was clearly observed in vitro
throughWestern blot (Figure 10, A and B) and IF (Figure 11C)
24 and 48 hours after 30 minutes of incubation with 100 M
hydrogen peroxide (H2O2). SOD2 was also increased in total
podocyte cell lysate (Supplemental Figure 7). Increase of AR
expression on plasmamembrane was not evident (Figure 11C)
and was only minimally appreciable in the cytoplasm (Supple-
mental Figure 7).
DISCUSSION
PrimaryMNis theprototypeofnephropathyassociatedwith sub-
epithelial immune deposits. Themechanism responsible for their
Figure 6. AR and SOD2 co-localize with IgG4 in glomeruli of MN patient biopsies. (A, B, D, and E) Confocal images of a renal biopsy
specimen from a patient with MN. Double IF staining was evaluated for AR (A), SOD2 (D) and IgG4 (B and E). Merged images are
reported in C and F and in p1 and p2. Both AR and SOD2 were co-localized with IgG4 along the capillary walls. Magnification, 630.
Figure 7. AR and SOD2 co-localize with C5b-9 in glomeruli of MN patient biopsies. Confocal images of a renal biopsy specimen from
MN. (A, B, D, and E) Double IF staining for AR (A), SOD2 (D), and C5b-9 (B and E). Merged images are reported in C and F and in p1
and p2. Both AR and SOD2 co-localize in immune deposits. Magnification, 630.
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formation and trapping within GBM has been extensively inves-
tigated in experimental models of HN. In this case, anti-megalin
autoantibodies co-localize in glomeruli withC5b-9 and clusterin.
The body of evidence for new antigens expressed in patients with
MNisnowgrowing.Debiec et al.11,12 showed thatNEPemerges as
antigen in patients with NEP deficiency and alloimmunization
during pregnancy. More recently, Beck et al.16 showed specific
IgG4 against PLA2R in glomerular eluates and in plasma of a rel-
evant part of patients withMN.
A critical point is to define whether other podocyte antigens
are recognized by IgG4 eluted from microdissected glomeruli.
We used Western blot with podocyte extract in both reducing
and nonreducing conditions to confirm the presence a few
antigens in podocytes. In the first approach, we could detect
eight proteins reacting with glomerular IgG4; in nonreducing
conditions, three more proteins with a higher molecular
weight were recognized, one of which had the same dimension
of PLA2R. Podocyte antigens recognized by electroeluted
(from glomeruli) and circulating IgG4 were characterized by
mass spectrometry and matched to extend studies with IEM
and IF to other patients with MN. AR and SOD2 emerged as
the two major podocyte components recognized by both cir-
culating and glomerular IgG4. In particular, we found a
marked increase in levels of circulating anti-AR and anti-SOD2
IgG4 in patients withMN compared with normal sera or other
idiopathic nephrotic syndromes (FSGS).
Moreover,de novo expressionof bothAR
and SOD2 and co-localization with IgG4
andC5b-9were observed inMNbiopsies
while being absent in other glomerular
pathologies. Ultrastructural study clearly
assessed localization of AR and SOD2 in
podocyte cytoplasm and foot processes
and in electron-dense subepithelial im-
mune deposits. Taken together, these
findings demonstrate that AR and SOD2
are neo-expressed proteins in MN glo-
meruli and that both are recognized by
specific circulating antibodies that can
also be detected in glomerular subepi-
thelial immune deposits. The preva-
lence of IgG4 in glomerular immune
deposits confirms the concept of an iso-
type-specific deposition mechanism;
therefore, AR and SOD2 should be
considered glomerular antigens impli-
cated in the immune process and actu-
ally belong, with NEP and PLA2R and
with the new panel of antigens cur-
rently under investigation (G.M.G.,
personal observation), to the list of an-
tigens recognized in human MN.
A crucial point still remains unre-
solved.Our data, in fact, cannot be con-
sidered exhaustive with respect to the
initial trigger event of MN in humans. Neo-expression of both
AR and SOD2 may, in fact, represent a continuation mecha-
nism after an initiation phase in which the basic event is dep-
osition of anti-PLA2AR, anti-NEP, and/or other, unrecog-
nized antibodies. The basic issue regarding the significance of
both neo-antigens in glomeruli of patients with MN will re-
quire further investigation, although the presence of anti-AR
and anti-SOD2 IgG4 in glomeruli at the time of diagnosis of
MN and its absence in other autoimmune renal pathologies
strongly supports a causal role in MN pathogenesis. A defini-
tive explanationwillmostly relyonanimalmodelsoverexpressing
AR and SOD2. Ongoing experiments for AR are experiencing
problems and will demand more time to be set up because of a
toxic effect of AR overexpression (data not shown).
Despite the previously highlighted doubts, our data support
the concept that neo-expressionofARandSOD2may represent a
key event in the natural history of the disease. For this purpose, a
series of preliminary in vitro experiments aimed at defining the
mechanisms regulating glomerular expression of both neo-anti-
gens were set up from already known data about their structure
and function. AR belongs to the family of aldo-keto reductases
catalyzing NADPH-dependent reduction of aliphatic and aro-
matic aldehydes and ketones. Its specific role is to convert glucose
into sorbitol, and it is involved in regulation of tissue tonicity and
osmolality.17 The enzyme also catalyzes the transformation of
Figure 8. Glomerular eluates from MN patients contain antibodies against podocyte
antigens. Podocyte extracts were separated by electrophoresis in reducing (a through e)
and nonreducing (f through h) conditions and were studied for reactivity with eluates from
microdissected glomeruli. Thirty micrograms of protein was used for the analysis: Part was
analyzed with silver stain (a and f), and part was incubated with glomerular eluates from
patients with MN and then developed with anti-IgG4 (b and g). Eight antigens were
recognized in reducing conditions and characterized by mass spectrometry as AR, SOD,
and vimentin. Three more bands with a molecular weight of 200, 170, and 155 kD were
detected in nonreducing conditions. (c and h) Control lines for Western blot in which
glomerular eluates were omitted. (d) Western blot with anti-AR antibody. (e) Western blot
with SOD2 antibodies.
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aldehydes, generated upon oxidation of unsaturated fatty ac-
ids.18 Localization of ARwithin the normal kidney is limited to
tubular epithelial cells of themedulla, and it is absent in normal
glomeruli.19,20
SOD2 is a crucial component of the extensive antioxidant cell
protective system, transforming toxic superoxide ions into H2O2
and diatomic oxygen. In the kidney, SOD2 is widely expressed in
tubular epithelial cells, especially in the cortex, where it plays a
central role in preserving the kidney during ischemia reperfusion
events, but it has never been reported in glomeruli.
The hypothesis, inferred from function of both AR and
SOD2 proteins, is that their expression is modified upon oxi-
dative stress induction. In vitro studies on immortalized hu-
man podocytes undergoing controlled oxidation by H2O2 ad-
ministration showed a significant upregulation mainly of
membrane SOD2 24 hours after treatment, whereas induction
of AR seems less specific. These results partially confirmdata of
the literature on the effects of oxidation on AR and SOD2,
Figure 10. Glomerular eluates from other pathologies do not
contain antibodies against AR or SOD2. Dot blot of eluates from
microdissected glomeruli of a normal kidney (N) and patients (n 7)
with other glomerulonephritis implying IgG deposition in glomeruli:
Systemic lupus nephritis (SLE; n  5) and membranoproliferative
glomerulonephritis (MPGN; n  2). For comparison, two patients
with MN were displayed. Anti-AR and anti-SOD IgG4 was deter-
mined as described in the Concise Methods section. Total IgG titer
was determined with dot blot to nonsaturated nitrocellulose mem-
brane, and proteins were revealed with biotinylated anti-human IgG.
Figure 9. Glomerular eluates from MN patients contain antibod-
ies against AR and SOD2. (A) Glomeruli showed presence of
specific IgG4 antibodies against AR and SOD2. IgGs were also
present at a lower titer. Controls were incubated with human
serum albumin (HSA) instead of glomerular eluates. (B) Corre-
sponding bar graph shows dot-spot OD (in arbitrary units) for
anti-AR (f) and anti-SOD2 () specific IgG4. (C) Competition
experiment using the same glomerular eluates as in A and in-
creasing amount of r-AR and r-SOD2 from 5 to 15 ng.
Figure 11. In vitro oxidation modifies AR and SOD2 expression
on plasma membrane. (A through C) Western blot (A), corre-
sponding bar graph (B; f, AR;, SOD2) and IF staining (C) for AR
or SOD2 upon H2O2 treatment. H2O2 treatment increased SOD2
expression at 24 and 48 hours, whereas AR was only slightly
affected. IF on nonpermeabilized podocytes confirmed Western
blot results. Magnification, 630.
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because both up- and downregulation of these proteins have
been previously reported.21–23
The idea that oxidative stress does occur inMN is not new. In
reference to HN,24 glomerular damage was demonstrated
tobemediatedbypodocyte-producedoxygenradicals in thepres-
ence ofC5b-9.25 Treatmentwith the scavenger probucol reduced,
in fact, both immune deposits and glomerular damage,3 suggest-
ing a successful use to reduce proteinuria in humanMN.26
In conclusion, our data clearly show a de novo glomerular ex-
pressionofARandSOD2 in idiopathicMNnephropathy.ARwas
only minimally and partially observed in non-MN glomeruli,
whereas SOD2 was completely absent in other renal pathologies.
Confocal IF and IEM assessed presence of both AR and SOD2 in
glomeruli of biopsies of patients with MN. Both antigens were
present in immune electron-dense deposits and were found in
close associationwith IgG4 andC5b-9. Specific anti-AR and anti-
SOD2 IgG4 was eluted from isolated MN glomeruli, thus con-
firmingbothproteins as targets of the autoimmuneprocess.High
titer of circulating anti-AR and anti-SOD2 IgG4was finally recog-
nized in a relevant part of the same MN cohort. In vitro experi-
ments showed that SOD2 is upregulated byH2O2, possibly impli-
cating oxidative stress in its plasma membrane neo-expression.
Regulation of AR and SOD2 within podocytes and formation of
autoantibodies should play a central role in the onset and/or
maintenance ofMN.
CONCISE METHODS
Patients
Twenty-four patients with MN were enrolled in the study. Seven-
teen underwent a complete screening for circulating autoantibod-
ies (Western blot and dot-blot assay); sera from seven patients
were used for the determination of serum titer of anti-AR and
anti-SOD2 autoantibodies with dot blot. Criteria for enrollment
were (1) a biopsy-based diagnosis of MN and (2) negative tests for
autoantibodies (ANA, nDNA, and ANCA) and cryoglobulins and
the absence of viral markers (hepatitis B surface antigen and HIV),
with the exception of hepatitis C virus antibody, which was present
in three patients. Furthermore, one additional patient, suspected
of being affected by secondary MN because of cachexia and biliary
duct obstruction, was included in the study. Although the clinical
status was highly suggestive of cancer, histologic demonstration of
malignant neoplasia could not be achieved. For histologic evalua-
tion of kidney disease, Dubosq-Bresil solution-fixed tissues were
embedded in paraffin, sectioned, and stained with hematoxylin/
eosin, Masson trichrome, silver methenamine, and periodic acid-
Schiff. Specimens for EM were fixed in Karnovsky solution and
processed using standard methods. IgG, IgA, IgM, C1q, C3, and
fibrinogen depositions were detected by direct IF staining on fro-
zen sections. Blood from the cohort described was obtained the
day before renal biopsy and after centrifugation at 1.55  g for 15
minutes at 4°C, was immediately stored at 80°C. At that time,
patients were not receiving any therapy.
Normal Kidneys and Other Nephropathies for IF
Studies
Overall, seven kidneys with other nephropathies (minimal-change
nephropathy, n 2; IgA nephropathy, n 2; type 2 diabetes, n 2)
and noncarcinomatous portions of kidneys (n 3) removed for renal
cancer were used as negative control.
Normal Kidneys and Other Nephritis for
Microdissection
Glomeruli were microdisseted with laser capture (see the Laser Cap-
ture Microdissection and Elution of Antibodies from Renal Biopsy
Tissue section) from renal tissues of patients withMN (n 3, patients
8, 11, and 12).Normal kidney (n 1) and renal biopsies frompatients
with class III or IV lupus nephritis (females, 11 to 18 years, n 5) and
with membranoproliferative nephritis (n  2) were microdissected
with the same technique. With the exception of normal kidneys, IF
revealed deposition of IgG along the glomerular membrane in all
other cases.
Antibodies
AR.
Polyclonal goat antibody used for human AR protein identification
was purified in the laboratory of P.K. Preparation and specificity test-
ing of antibodies were performed as described previously27,28 and are
summarized in Supplemental Methods.
SOD2.
Purified rabbit antiserum against human SOD2 was purchased from
Upstate Biotechnologies (Charlottesville, VA). Mouse mAb (clone
G1D4-IgG1; Progen Biotechnik, Heidelberg, Germany) against hu-
man synaptopodin andmousemonoclonal serum anti-humanC5b-9
(clone aE11-IgG2a, ; Dako) were used in this study.
IgG4.
Purified mouse mAb to human IgG4 (clone HP6025, IgG1-K) was
purchased from Invitrogen (Camarillo, CA).
Secondary Antibodies.
Affinity-purified FITC F(ab)2 donkey anti- human IgG, affinity-pu-
rified FITC and Texas Red–conjugated donkey anti-goat IgG, and
donkey anti-rabbit IgG and FITC affinity-purified donkey anti-
mouse IgG all were purchased from Jackson Immunoresearch (West
Grove, PA). For IEM, donkey anti-goat or anti-rabbit IgG conjugated
with 12 nm of colloidal gold particles (Jackson Immunoresearch) was
used.
IF Staining for AR and SOD2
Renal biopsy specimens were embedded in OCT (Tissue Tek, Miles,
Elkhart, IN) and stored in liquid nitrogen. Samples were cut into
3-m sections by a cryostat (Leica CM1850; Leica Mycrosystems,
Heerbrog, Germany) and placed on poly-L-lysine–coated glass slides
for indirect immunostaining. Cryosections were fixed in modified
Carnoy solution for 10 minutes at 4°C and subsequently washed in
PBS. Nonspecific binding was blocked by incubation in BSA 3% wt/
vol in PBS for 20 minutes at room temperature. Sections were then
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incubated for 2 hours at room temperaturewith primary goat anti-AR
or rabbit anti-SOD2 antibody diluted in PBS 1:150 or 1:50, respec-
tively.
FITC-conjugated donkey IgG anti-goat (1:50) and FITC-conju-
gated donkey IgG anti-rabbit (1:20) were used as secondary antibod-
ies. Competition experiments performed with anti-AR or anti-SOD2
antibodies preincubated for 4 hours at 37°C with an excess of AR or
SOD2 protein, respectively, gave negative results (Supplemental Fig-
ure 4). Negative controls were processed in parallel using an equiva-
lent concentration of a normal goat or rabbit antiserum as primary
antibody, respectively.
Co-localization and Confocal Microscopy Analysis
For double-staining indirect IF and co-localization analysis, Carnoy
fixed cryosections were incubated with blocking solution (3% wt/vol
BSA in PBS) and in succession with FITC donkey anti-human IgG
F(ab)2 (1:20) for 2 hours at room temperature. After additional PBS
washes, slides were then exposed to a diluted polyclonal goat serum
anti-AR (1:150) or rabbit serumanti-SOD2 (1:50) for 2 hours at room
temperature. The presence of AR and SOD2 proteins was revealed by
incubation of Texas Red–conjugated donkey IgG anti-goat and anti-
rabbit, respectively. IgG4 deposits were characterized using purified
anti-human IgG4 mouse mAb (Invitrogen).
For C5b-9 and AR or SOD2 co-localization, Carnoy fixed sections
were incubated in primary step with anti–C5b-9 mAb diluted (1:10)
for 2 hours at room temperature and revelated by FITC-conjugated
donkey IgG anti-mouse diluted (1:20) in PBS. AR and SOD2 were
detected as described already. Samples were observed using a confocal
system (LSM 510Meta scan head integrated with the Axiovert 200 M
inverted microscope; Carl Zeiss, Jena, Germany) with a 63 oil ob-
jective. Image acquisitionwas carried out inmultitrackmode, namely
through consecutive and independent optical pathways.
Electron Microscopy
Small fragments of the kidney biopsies were fixed in Karnovsky solu-
tion and processed according to standard methods omitting postfix-
ation in osmium tetroxide.29 Osmication of tissues was omitted to
avoid masking of antigenic sites as previously reported in the litera-
ture.30
After exposure with a blocking agent (BSA 3% wt/vol in PBS),
ultrathin sections were incubated overnight with anti-AR (diluted
1:200) and anti-SOD2 (diluted 1:50) antibodies. Immune reaction
was then revealed using donkey anti-goat or anti-rabbit IgG conju-
gated with 12 nm of colloidal gold particles.
The specificity and validity of the labeling were verified by substi-
tuting primary antibody with the same antibody preincubated with
nonimmune goat or rabbit serum (see Supplemental Figure 5) or
alternatively be substituting primary antibody with PBS. After coun-
terstainingwith uranyl acetate and lead citrate, ultrathin sectionswere
examined and micrographs were taken using a Philips EM208 trans-
mission electron microscope (Philips Electron Optics, FEI, Eind-
hoven, Netherlands).
Cell Culture
A human conditionally immortalized podocyte cell line31 was cul-
tured in RPMI 1640 supplemented with 10% inactivated FCS, insulin
transferrin selenium, 100 U/ml penicillin, and 100 mg/ml streptomy-
cin. Cells were expanded at 33°C. For IF, cells were plated in 6-cm
Petri dishes at a density of 3.5 ° 103 cells/cm2 and differentiated for 15
days at 37°C in 5% CO2/95% air. The same cell line was used for the
oxidation experiments (see the In Vitro Oxidation section).
Detection of Circulating Antibodies against Podocyte
Proteins
Detection of anti-podocyte antibodies in sera of patientswithMNwas
assessed by Western blot of podocyte cell line membrane extracts
separated by 2Delectrophoresis (see supplementalmaterial).Detailed
technique for transblot and detection is described in the Supplement
Methods section. Formembrane preparation, subconfluent cells were
homogenized in cold hypotonic solution containing 5mMphosphate
buffer (pH 7.4), 0.15%wt/vol n-Hexyl-D-glucopyranoside (Calbio-
chem), and protease inhibitor cocktail. Homogenates were centri-
fuged at 14,000 rpm for 15 minutes, and supernatant containing cy-
toplasm proteins was discarded. Pellets were resuspended in 150 mM
NaCl, 0.5% vol/vol Triton X-100, 0.25% wt/vol natrium desoxy-
cholate, and 50 mM phosphate buffer (pH 7.4) and centrifuged at
14000 rpm for 15 minutes. Supernatants containing membrane pro-
teins were collected, and protein concentration was determined using
BCA assay.
2D Electrophoresis
2D electrophoresis was performed in soft gels as described previ-
ously32 (see the Supplemental Methods section).
Gel/Membrane Staining and Image Analysis
After separation in SDS-PAGE gels, proteinswere visualized by a dou-
ble-staining procedure: First, methyl-trichloroacetate–negative stain-
ing,33 then silver staining or Blue silver colloidal or Coomassie for
preparative mass spectrometry analysis (see the Supplemental Meth-
ods section).
Tryptic Digestion and Protein Identification by MALDI-
TOF
Details of MALDI-TOF are given in the Supplemental Methods sec-
tion.
Dot-Blot Analysis for Circulating Anti-AR and Anti-
SOD2 Levels
The titer of circulating autoantibodies (IgG4) in sera of patients with
MN (n  24), normal control subjects (n  24), or children with
idiopathic nephrotic syndrome (n 8) was determined with dot blot
using r-AR (300 ng) and r-SOD2 (300 ng) as immobilized antigens.
Purity of both recombinant proteins was confirmed by monodimen-
sional electrophoresis (Supplemental Figure 3). The technique for dot
blot is described in the Supplemental Methods section.
Laser Capture Microdissection and Elution of
Antibodies from Renal Biopsy Tissue
Cryostatic sections (5m) of kidney tissue specimens were placed on
metal frame slides with thermoplastic membrane (Molecular Ma-
chines & Industries AG; Glattburg, Zurich, Switzerland), stained, and
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dehydrated using an ArcturusHistoGene, LCMFrozen Section Stain-
ing Kit (Arcturus Bioscience, Mountain View, CA) according to the
manufacturer’s instructions. Air-dried sections were then viewed
with the NIKON ECLIPSE-TE 2000 inverted microscope (Nikon-
Instruments, Sesto Fiorentino, Italy). Glomeruli were identified and
isolated with the Molecular Machines & Industries Cellcut LMD sys-
tem by focal melting of the membrane through laser activation. The
MolecularMachines & Industries Cellcut Laser CaptureMicrodissec-
tion system is equipped with a solid-state ultraviolet laser that guar-
antees precise cutting without damaging the tissue. High precision
xy-stage and CCD camera allow identification, documentation, and
dissection of multiple regions of interest from the same tissue speci-
men. For each specimen, a total of 25 to 30 glomeruli were microdis-
sected and removed sequentially in separate isolation cap (Nikon In-
struments) with special adhesive material in the lid.
After visual control of the completeness of dissection, captured
tissue was immersed in denaturation buffer and used for proteomic
analysis. Sections of human kidney derived from noncarcinomatous
portions of kidneys removed for renal carcinoma were used as nega-
tive control. Igs were recovered from glomeruli by means of acid
elution as described previously.34 Briefly, after washings with PBS
(0.01 M, pH 7.2) groups of 20 glomeruli were incubated overnight
with 0.02 M citrate buffer (pH 3.2) at 4°C in a humid atmosphere.
After removal of citrate buffer, 0.4 M NaOH was added to achieve a
pH of 7.2. Dot-blot analysis for anti-AR and anti-SOD2 IgG and IgG4
in glomerular eluates was performed as already described (see also the
Supplemental Methods section). Total IgGs were determined by the
same dot-blot assay in which 50 l of sample had been applied to
nonsaturated nitrocellulose membranes and IgGs were revealed with
biotinylated anti-human IgG antibodies.
Cell Studies
For IF, human podocyte cell lines were gently washed in RPMI/2%
HEPES buffer and fixed for 20 minutes at 37°C in 1% paraformalde-
hyde dissolved in RPMI/2% HEPES buffer. Details for cell culturing
and interaction with MN serum are given in the supplemental mate-
rial.
Podocyte Surface Biotin Labeling
Subconfluent adherent cells were rinsed three times in ice-cold PBS,
and cell surfaces were labeled with the appropriate volume of 230M
EZ-linf sulfo-NHS-LC-LC-biotin (Pierce, Rockford, IL). The reac-
tionwas performed for 5minutes at 4°C. Cells were rinsed three times
in ice-cold TBS to quench and remove the excess of biotin reagent.
Membranes were prepared as described in the section Detection of
Circulating Antibodies against Podocyte Proteins. Podocyte mem-
brane extracts (200g) were run on a 2D electrophoresis as described
in the supplementalmaterial and transferred to a nitrocellulosemem-
brane saturated in 3%wt/vol BSA inTBS and incubatedwith 50 pg/ml
Neutravidin in 1%wt/vol BSA in TBS-Tween 0.15% vol/vol (TBS-T).
Chemiluminescence was used for immunodetection. Images were
digitalized by VersaDoc 4000 (Bio-Rad, Hercules, CA) and analyzed
with QuantityOne and PDQuest software (Bio-Rad).
In Vitro Oxidation
For in vitrooxidation, humanpodocyte cell linewasmaintained inRPMI
1640mediumwith 10% vol/vol FCS, 20mMglutamine, 100 IU/ml pen-
icillin, 100 IU/ml streptomycin, 5g/ml insulin, 5g/ml transferrin, and
5 ng/ml sodium selenite at 37°C in a 10% CO2 humidified incubator.
Cells at 70 to 80% confluence were rinsed twice with serum-deprived
RPMI 1640 and stimulated with 125MH2O2 for 0, 18, or 24 hours by
addition to the growth serum-deprivedmedia. Cells were harvested after
the indicated times, rinsed three times with PBS, and lysed in 2D buffer
(see the two-dimensional electrophoresis section in the Supplemental
Methods). Membrane preparation was done following the same proce-
dure described already.
Statistical Analysis
Nonparametric Mann-Whitney U test was used for comparison of
anti-AR and anti-SOD2 IgG4 serum titer in patients with MN versus
control subjects. Results were given as median. Parametric t test was
used for comparing results deriving from morphometric analysis of
renal AR and SOD2 expression. Results were give as means SEM.
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